VR Logo

AnaptysBio Inc. (ANAB) download report


Healthcare | Biotechnology & Pharma Research

AnaptysBio Inc. (ANAB) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

IPO Date: 26-Jan-2017

Interim Pres & CEO and Director: Mr. Daniel R. Faga

COO & Gen. Counsel: Mr. Eric J. Loumeau

Listing: NASDAQ: ANAB

Country: United States

Headquarters: San Diego, CA

Website: https://www.anaptysbio.com

Key Facts

Market cap: $589.09 Mln

Revenue (TTM): $52.90 Mln

Earnings (TTM): $-75.89 Mln

Cash: $505.62 Mln

Total Debt: $20.60 Mln

Insider's Holding: 0.35%

Liquidity: Low

52 Week range: $18.20 - 37.89

Shares outstanding: 28,186,100

9 Years Aggregate:

  • CFO: $-207.43 Mln
  • EBITDA: $-267.31 Mln
  • Net Profit: $-278.47 Mln

Stock Performance

Time Period AnaptysBio (ANAB) S&P BSE Sensex S&P Small-Cap 600
YTD-41.94-8.99-19.23
1 month2.67-3.40-9.35
3 months-20.51-8.50-16.59
1 Year-21.470.89-17.36
3 Years-29.0210.415.90
5 Years-4.0511.435.77
10 Years--11.779.78
As on 30-Jun-2022
Year AnaptysBio (ANAB) S&P Small-Cap 600 S&P BSE Sensex
202161.6325.2721.99
202032.319.5715.75
2019-74.5320.8614.38
2018-36.51-9.705.87